# Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

> **NCT04079101** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 31 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BIIB104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04079101
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-02
- **Primary completion:** 2019-12-27
- **Final completion:** 2019-12-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079101, "Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04079101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*